Details for Patent: 7,919,598

Which drugs does patent 7,919,598 protect, and when does it expire?

Patent 7,919,598 protects QTERNMET XR, QTERN, XIGDUO XR, and FARXIGA, and is included in four NDAs.

Protection for XIGDUO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-eight patent family members in thirty-two countries.

Summary for Patent: 7,919,598

Title:	Crystal structures of SGLT2 inhibitors and processes for preparing same
Abstract:	The present invention relates to physical crystal structures of a compound of the formula I: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.2a, R.sup.3 and R.sup.4 are as defined herein, especially ##STR00002## pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
Inventor(s):	Gougoutas; Jack Z. (Princeton, NJ), Lobinger; Hildegard (Regensburg, DE), Ramakrishnan; Srividya (Milltown, NJ), Deshpande; Prashant P. (Princeton, NJ), Bien; Jeffrey T. (Princeton, NJ), Lai; Chiajen (Kendall Park, NJ), Wang; Chenchi (Somerset, NJ), Riebel; Peter (Ruhstorf a.d. Rott, DE), Grosso; John Anthony (Princeton Junction, NJ), Nirschl; Alexandra A. (Yardley, PA), Singh; Janak (Lawrenceville, NJ), DiMarco; John D. (East Brunswick, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	11/765,481
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,919,598
Patent Claim Types: see list of patent claims	Compound; Use; Process;

Drugs Protected by US Patent 7,919,598

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-001	May 2, 2019		DISCN	Yes	No				Y
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-002	May 2, 2019		DISCN	Yes	No				Y
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-003	May 2, 2019		DISCN	Yes	No				Y
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-004	May 2, 2019		DISCN	Yes	No				Y
Astrazeneca Ab	QTERN	dapagliflozin; saxagliptin hydrochloride	TABLET;ORAL	209091-002	May 2, 2019		RX	Yes	No				Y

International Family Members for US Patent 7,919,598

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061730
Australia	2007265246
Brazil	122017015106
Brazil	122017021516
Brazil	PI0713544